Barclays PLC Reports 5.65% Passive Stake in Amicus Therapeutics Inc (FOLD)

On May 14, 2026, Barclays PLC filed a Schedule 13G with the SEC, reporting a new ownership stake in Amicus Therapeutics, Inc. (FOLD). As of the event date on March 31, 2026, the London-based financial institution disclosed beneficial ownership of 17,755,672 shares of common stock, representing 5.65% of the company. The filing indicates that Barclays PLC holds sole voting and dispositive power over 17,747,658 shares, with shared power over the remaining 8,014 shares. The position is held through several subsidiaries, including Barclays Bank PLC, Barclays Capital Inc., and Barclays Capital Securities Ltd. This filing was made under Rule 13d-1(b), signifying that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. This marks an increase from a previously unreported or zero position, crossing the 5% regulatory threshold.